Targeting the interaction between the C-terminal domain of the GluA2 subunit of AMPAR and brefeldin-resistant Arf-GEF 2 (BRAG2), a guanine nucleotide exchange factor for the small GTPase Arf6, presents a potential therapeutic approach for acute ischemic stroke.